Department of Public Health, Wakayama Medical University School of Medicine, Wakayama, Japan.
Department of Molecular-Targeting Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Cancer Res Commun. 2022 Jun 23;2(6):483-488. doi: 10.1158/2767-9764.CRC-22-0088. eCollection 2022 Jun.
Aspirin has gained great attention as a cancer preventive agent. Our previous study revealed that the low-dose aspirin prevents colorectal tumor recurrence in Japanese patients with colorectal adenomas and/or adenocarcinomas, whereas aspirin increases risks in smokers and has no effects on regular drinkers. Our recent study revealed that aspirin reduces polyp growth in Japanese patients with familial adenomatous polyposis (FAP). In this study, we have studied the association of genotypes of alcohol metabolizing enzymes (ADH1B and ALDH2) on aspirin's efficacy of suppressing polyp growth (≥5 mm) in a total of 81 Japanese patients with FAP. Our study revealed that aspirin showed significant preventive effects for patients with -AA and AA+GA types [OR = 0.21; 95% confidence interval (CI), 0.05-0.95, and OR = 0.31; 95% CI, 0.10-0.95, respectively], and for patients with -GG and GG+GA types (OR = 0.10; 95% CI, 0.01-0.92, and OR = 0.29; 95% CI, 0.09-0.94, respectively), but not for patients with -GG and GA+GG types, and -AA and GA+AA types. In addition, substantial preventive effects of aspirin were seen for patients with -AA type who do not drink regularly (<3 times/week, OR = 0.11; 95% CI, 0.02-0.78), where a statistically significant interaction between aspirin and was observed ( = 0.036). Results from this exploratory study strongly indicate that aspirin is beneficial in prevention of polyp growth for patients with FAP with -AA and AA+GA types, and -GG and GG+GA types. Taken together, we propose and as candidate markers for the personalized prevention by aspirin.
Aspirin is beneficial to patients with FAP with -AA and AA+GA types or -GG and GG+GA types. and genotypes can be the markers for the personalized prevention of colorectal cancer by aspirin.
阿司匹林作为一种癌症预防剂引起了广泛关注。我们之前的研究表明，低剂量阿司匹林可预防日本结直肠腺瘤和/或腺癌患者的结直肠肿瘤复发，而阿司匹林会增加吸烟者的风险，对经常饮酒者则没有影响。我们最近的研究表明，阿司匹林可减少日本家族性腺瘤性息肉病（FAP）患者的息肉生长。在这项研究中，我们研究了酒精代谢酶（ADH1B 和 ALDH2）的基因型与阿司匹林抑制息肉生长（≥5mm）的疗效之间的关系，共纳入 81 例日本 FAP 患者。我们的研究表明，阿司匹林对 -AA 和 AA+GA 型患者具有显著的预防作用[OR=0.21；95%置信区间（CI），0.05-0.95 和 OR=0.31；95%CI，0.10-0.95]，对 -GG 和 GG+GA 型患者也具有显著的预防作用[OR=0.10；95%CI，0.01-0.92 和 OR=0.29；95%CI，0.09-0.94]，但对 -GG 和 GA+GG 型和 -AA 和 GA+AA 型患者则没有这种作用。此外，对于不经常饮酒（<3 次/周）的 -AA 型患者，阿司匹林也具有显著的预防作用（OR=0.11；95%CI，0.02-0.78），阿司匹林与之间存在统计学显著的交互作用（=0.036）。这项探索性研究的结果强烈表明，阿司匹林对 -AA 和 AA+GA 型或 -GG 和 GG+GA 型 FAP 患者的息肉生长有预防作用。综上所述，我们提出和作为阿司匹林个体化预防的候选标志物。
阿司匹林对 -AA 和 AA+GA 型或 -GG 和 GG+GA 型 FAP 患者有益。和基因型可以作为阿司匹林预防结直肠癌的个体化标志物。
